<p>/PRNewswire/ -- 根据 MarketsandMarkets™的报告，<strong>癌症生物标志物市场</strong> 预计将从 2026 年的约 282.5 亿美元增长到 2032 年的 544.8 亿美元，年均增长率为 11.6%。</p>
<p><strong>浏览关于&#34;癌症生物标志物市场 - 全球预测到 2032 年&#34;的 493 个市场数据表和 50 个图表，涵盖 550 页及详细目录</strong></p>
<p><strong>癌症生物标志物市场规模及预测：</strong></p>
<ul>
<li><strong>可用市场规模年份：</strong> 2025–2032</li>
<li><strong>2026 年市场规模：</strong> 282.5 亿美元</li>
<li><strong>2032 年预计市场规模：</strong> 544.8 亿美元</li>
<li><strong>年均增长率（2026–2032）：</strong> 11.6%</li>
</ul>
<p><strong>癌症生物标志物市场趋势与洞察：</strong></p>
<ul>
<li>诊断细分市场在 2025 年占据 51.0% 的市场份额。</li>
<li>消耗品细分市场预计将注册最高的增长率，达到 12.0%。</li>
<li>北美在 2025 年占据市场份额的领先地位。</li>
</ul>
<p><strong>下载 PDF 手册 @</strong> https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202</p>
<p>市场的增长主要归因于生物标志物在肿瘤治疗方法中的应用，以及全球癌症发病率的上升。其他导致癌症生物标志物市场显著增长的因素包括精准医疗的使用以及通过基因组学、蛋白质组学和多组学识别生物标志物的创新方法。</p>
<p>尽管上述积极因素存在，但市场内仍存在某些限制。进行复杂诊断程序（如下一代测序和多组学）所需的高成本，成为其更频繁使用的障碍，尤其是在发展中国家。此外，保险覆盖问题也是阻碍许多患者接受基于生物标志物的诊断的障碍。在考虑这些测试时，还需要考虑采样和处理的变异性等问题。</p>
<p><strong>在癌症生物标志物市场中，组学技术细分市场在 2026 年占据了分析技术细分市场的最大份额。</strong></p>
<p>癌症生物标志物市场根据分析方法分为两个细分市场：组学技术和成像技术。截至 2025 年，癌症生物标志物市场由组学技术细分市场主导，主要是由于这些技术在癌症生物标志物发现和诊断中的高通量特性。</p>
<p><strong>请求样本页面 @</strong> https://www.marketsandmarkets.com/requestsampleNew.asp?id=202</p>
<p><strong>在癌症生物标志物市场中，乳腺癌细分市场在 2026 年占据了癌症类型细分市场的最大份额。</strong></p>
<p>癌症生物标志物市场按癌症类型分为：非霍奇金淋巴瘤、肾癌、膀胱癌、甲状腺癌、乳腺癌、肺癌、结直肠癌、前列腺癌、黑色素瘤、白血病及其他癌症类型。到 2025 年，癌症生物标志物市场由乳腺癌细分市场主导。该细分市场的巨大份额是由于全球乳腺癌病例的增长，以及对诊断、预防和治疗的认识提升。</p>
<p><strong>北美在 2026 年主导了癌症生物标志物市场。</strong></p>
<p>癌症生物标志物市场分为六个地区：亚太地区、拉丁美洲、北美、欧洲、中东和非洲，以及海湾合作委员会国家。北美在 2026 年占据癌症生物标志物市场的最大份额。该地区市场的增长得益于其医疗基础设施、高癌症发病率以及进行的诊断测试数量增加。该地区对癌症生物标志物的高需求受到高端诊断中心和医院的存在，以及对诊断准确性、质量和早期疾病检测的严格监管要求的推动。</p>
<p><strong>购买前咨询 @</strong> https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=202</p>
<p><strong>癌症生物标志物市场的顶级公司：</strong></p>
<p>癌症生物标志物市场的顶级公司包括 Thermo Fisher（美国）、Roche Hoffmann（瑞士）、Illumina（美国）、Quest Diagnostics（美国）和 Agilent Technologies（美国）。</p>
<p><strong>浏览相关市场：</strong> <strong>医疗设备市场研究报告与咨询</strong></p>
<p><strong>相关报告：</strong></p>
<p><strong>患者来源异种移植/PDX 模型市场</strong> <strong>- 全球预测到 2030 年</strong></p>
<p><strong>生物标志物市场</strong> <strong>- 全球预测到 2030 年</strong></p>
<p><strong>基因组学市场</strong> <strong>- 全球预测到 2030 年</strong></p>
<p><strong>精准诊断与医学市场</strong> <strong>- 全球预测到 2029 年</strong></p>
<p><strong>蛋白质组学市场</strong> <strong>- 全球预测到 2031 年</strong></p>
<p><strong>关于 MarketsandMarkets™</strong></p>
<p>MarketsandMarkets™被《福布斯》评选为美国最佳管理咨询公司之一，依据其最新报告。</p>
<p>MarketsandMarkets™是增长咨询和项目管理领域的蓝海替代方案，利用人机结合的服务推动 B2B 领域进步组织的超常增长。我们对新兴技术的广泛视角使我们能够与全球客户共同创造超常增长。</p>
<p>如今，80% 的财富 2000 强公司依赖于 MarketsandMarkets，且每个行业前 100 家公司中有 90 家公司信任我们以加速其收入增长。我们拥有超过 13000 个全球客户，帮助企业在颠覆性生态系统中蓬勃发展。</p>
<p>B2B 经济正在见证 25000 亿美元新收入流的出现，这些收入流将在本十年内取代现有收入流。我们与客户合作开展增长项目，帮助他们通过我们的服务线——市场规模扩展、市场进入（GTM）战略到执行、市场份额增长、客户启用和思想领导力营销，来实现这一 25000 亿美元的机会。</p>
<p>基于 “给予增长” 的原则，我们与多家《福布斯》全球 2000 强 B2B 公司合作，以保持其未来准备状态。我们的洞察和战略由行业专家、尖端人工智能和我们的市场情报云平台 KnowledgeStore™提供支持，该平台整合研究并提供生态系统范围内的收入变化可见性。</p>
<p>MarketsandMarkets™ SalesPlay 是一款基于人工智能的收入智能助手，旨在帮助收入团队优先考虑合适的客户，及早识别关键变化，并在需求来临之前发现机会，从而自然地建立销售管道，并以更高的一致性完成交易。</p>
<p>欲了解更多信息，请访问 www.MarketsandMarkets™.com 或关注我们的 Twitter、LinkedIn 和 Facebook。</p>
<p>联系方式：</p>
<p>罗汉·萨尔加尔卡尔（Mr. Rohan Salgarkar）</p>
<p>MarketsandMarkets™ INC.</p>
<p>南国会大道 1615 号</p>
<p>103 套房，德尔雷海滩，佛罗里达州 33445</p>
<p>美国：+1-888-600-6441</p>
<p>电子邮件：[email protected]</p>
<p>访问我们的网站：https://www.marketsandmarkets.com/</p>
<p>标志：https://mma.prnewswire.com/media/1868219/5909825/MarketsandMarkets_Logo.jpg</p>
<p>来源：MarketsandMarkets</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9SU82MTYxMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxMDMwUFJfTkVXU19VU1BSX19fX19JTzYxNjEy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9SU82MTYxMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxMDMwUFJfTkVXU19VU1BSX19fX19JTzYxNjEy"/></p>

罗氏(ADR)

赛默飞世尔

ILMN

<p>癌症生物标志物市场预计将从 2026 年的 282.5 亿美元增长到 2032 年的 544.8 亿美元，年均增长率为 11.6%。诊断部门将主导市场，而耗材部门预计将实现最快增长。北美预计将主导市场，原因在于其医疗基础设施和高癌症发病率。主要参与者包括赛默飞世尔、罗氏和 Illumina</p>

<p>, /PRNewswire/ -- According to MarketsandMarkets™, the <strong>Cancer Biomarkers Market</strong> is projected to grow from about USD 28.25 billion in 2026 to USD 54.48 billion by 2032, at a CAGR of 11.6%.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 根据 MarketsandMarkets™的报告，<strong>癌症生物标志物市场</strong> 预计将从 2026 年的约 282.5 亿美元增长到 2032 年的 544.8 亿美元，年均增长率为 11.6%。</p>
</div><p><strong>Browse 493 market data Tables and 50 Figures spread through 550 Pages and in-depth TOC on &#34;Cancer Biomarkers Market - Global Forecast to 2032&#34;</strong></p>
<div class="lb-trans"><p><strong>浏览关于&#34;癌症生物标志物市场 - 全球预测到 2032 年&#34;的 493 个市场数据表和 50 个图表，涵盖 550 页及详细目录</strong></p>
</div><p><strong>Cancer Biomarkers Market Size &amp; Forecast:</strong></p>
<div class="lb-trans"><p><strong>癌症生物标志物市场规模及预测：</strong></p>
</div><ul>
<li><strong>Market Size Available for Years:</strong> 2025–2032</li>
<li><strong>2026 Market Size:</strong> USD 28.25 billion</li>
<li><strong>2032 Projected Market Size:</strong> USD 54.48 billion</li>
<li><strong>CAGR (2026–2032):</strong> 11.6%</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>可用市场规模年份：</strong> 2025–2032</li>
<li><strong>2026 年市场规模：</strong> 282.5 亿美元</li>
<li><strong>2032 年预计市场规模：</strong> 544.8 亿美元</li>
<li><strong>年均增长率（2026–2032）：</strong> 11.6%</li>
</ul>
</div><p><strong>Cancer Biomarkers Market Trends &amp; Insights:</strong></p>
<div class="lb-trans"><p><strong>癌症生物标志物市场趋势与洞察：</strong></p>
</div><ul>
<li>The diagnostics segment leads the market with the share of 51.0% in 2025.</li>
<li>The consumables segment is expected to register the highest growth rate with 12.0%.</li>
<li>North America led the market share in 2025.</li>
</ul>
<div class="lb-trans"><ul>
<li>诊断细分市场在 2025 年占据 51.0% 的市场份额。</li>
<li>消耗品细分市场预计将注册最高的增长率，达到 12.0%。</li>
<li>北美在 2025 年占据市场份额的领先地位。</li>
</ul>
</div><p><strong>Download PDF Brochure @</strong> https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202</p>
<div class="lb-trans"><p><strong>下载 PDF 手册 @</strong> https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202</p>
</div><p>The growth in the market will primarily be attributed to the use of biomarkers in oncological treatment approaches, along with rising cancer rates worldwide. Other factors that have led to the substantial growth of the cancer biomarkers market include the use of precision medicines and innovative methods for identifying biomarkers through genomics, proteomics, and multi-omics.</p>
<div class="lb-trans"><p>市场的增长主要归因于生物标志物在肿瘤治疗方法中的应用，以及全球癌症发病率的上升。其他导致癌症生物标志物市场显著增长的因素包括精准医疗的使用以及通过基因组学、蛋白质组学和多组学识别生物标志物的创新方法。</p>
</div><p>Despite all the above-mentioned positive factors, there are certain limitations within the market. High costs required to perform complex diagnostic procedures, such as next-generation sequencing and multi-omics, pose an obstacle to their more frequent use, especially in developing countries. Moreover, issues with insurance coverage are another obstacle that prevents many patients from receiving biomarker-based diagnostics. Issues such as variability in sampling and processing also need to be considered when considering these tests.</p>
<div class="lb-trans"><p>尽管上述积极因素存在，但市场内仍存在某些限制。进行复杂诊断程序（如下一代测序和多组学）所需的高成本，成为其更频繁使用的障碍，尤其是在发展中国家。此外，保险覆盖问题也是阻碍许多患者接受基于生物标志物的诊断的障碍。在考虑这些测试时，还需要考虑采样和处理的变异性等问题。</p>
</div><p><strong>In the cancer biomarkers market, the omics technology segment accounted for the largest share within the profiling technology segment in 2026.</strong></p>
<div class="lb-trans"><p><strong>在癌症生物标志物市场中，组学技术细分市场在 2026 年占据了分析技术细分市场的最大份额。</strong></p>
</div><p>The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. As of 2025, the cancer biomarkers market was dominated by the omics technology segment, mainly due to the high-throughput nature of these technologies in cancer biomarker discovery and diagnosis.</p>
<div class="lb-trans"><p>癌症生物标志物市场根据分析方法分为两个细分市场：组学技术和成像技术。截至 2025 年，癌症生物标志物市场由组学技术细分市场主导，主要是由于这些技术在癌症生物标志物发现和诊断中的高通量特性。</p>
</div><p><strong>Request Sample Pages@</strong> https://www.marketsandmarkets.com/requestsampleNew.asp?id=202</p>
<div class="lb-trans"><p><strong>请求样本页面 @</strong> https://www.marketsandmarkets.com/requestsampleNew.asp?id=202</p>
</div><p><strong>In the cancer biomarkers market, the breast cancer segment accounted for the largest share within the cancer type segment in 2026.</strong></p>
<div class="lb-trans"><p><strong>在癌症生物标志物市场中，乳腺癌细分市场在 2026 年占据了癌症类型细分市场的最大份额。</strong></p>
</div><p>The market for cancer biomarkers is divided into categories by cancer type: non-Hodgkin lymphoma, kidney cancer, bladder cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancer types. In 2025, the market for cancer biomarkers was dominated by the breast cancer segment. The huge share of this segment is due to the growing rate of breast cancer cases worldwide, followed by awareness for diagnosis, prevention, and treatment.</p>
<div class="lb-trans"><p>癌症生物标志物市场按癌症类型分为：非霍奇金淋巴瘤、肾癌、膀胱癌、甲状腺癌、乳腺癌、肺癌、结直肠癌、前列腺癌、黑色素瘤、白血病及其他癌症类型。到 2025 年，癌症生物标志物市场由乳腺癌细分市场主导。该细分市场的巨大份额是由于全球乳腺癌病例的增长，以及对诊断、预防和治疗的认识提升。</p>
</div><p><strong>North America dominated the cancer biomarkers market in 2026.</strong></p>
<div class="lb-trans"><p><strong>北美在 2026 年主导了癌症生物标志物市场。</strong></p>
</div><p>The cancer biomarkers market is segmented into six regions: Asia Pacific, Latin America, North America, Europe, the Middle East &amp; Africa, and GCC Countries. North America held the largest market share in the cancer biomarkers market in 2026. The market in this region is growing due to its healthcare infrastructure, high cancer incidence, and increased number of diagnostic tests performed. High demand for cancer biomarkers in this region is driven by the presence of high-end diagnostic centers and hospitals, along with stringent regulatory requirements for diagnostic accuracy, quality, and early disease detection.</p>
<div class="lb-trans"><p>癌症生物标志物市场分为六个地区：亚太地区、拉丁美洲、北美、欧洲、中东和非洲，以及海湾合作委员会国家。北美在 2026 年占据癌症生物标志物市场的最大份额。该地区市场的增长得益于其医疗基础设施、高癌症发病率以及进行的诊断测试数量增加。该地区对癌症生物标志物的高需求受到高端诊断中心和医院的存在，以及对诊断准确性、质量和早期疾病检测的严格监管要求的推动。</p>
</div><p><strong>Inquire Before Buying@</strong> https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=202</p>
<div class="lb-trans"><p><strong>购买前咨询 @</strong> https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=202</p>
</div><p><strong>Top Companies in Cancer Biomarkers Market:</strong></p>
<div class="lb-trans"><p><strong>癌症生物标志物市场的顶级公司：</strong></p>
</div><p>The Top Companies in Cancer Biomarkers Market include Thermo Fisher (US), Roche Hoffmann (Switzerland), Illumina (US), Quest Diagnostics (US), and Agilent Technologies (US).</p>
<div class="lb-trans"><p>癌症生物标志物市场的顶级公司包括 Thermo Fisher（美国）、Roche Hoffmann（瑞士）、Illumina（美国）、Quest Diagnostics（美国）和 Agilent Technologies（美国）。</p>
</div><p><strong>Browse Adjacent Markets</strong>: <strong>Medical Devices Market Research</strong> <strong>Reports &amp; Consulting</strong></p>
<div class="lb-trans"><p><strong>浏览相关市场：</strong> <strong>医疗设备市场研究报告与咨询</strong></p>
</div><p><strong>Related Reports:</strong></p>
<div class="lb-trans"><p><strong>相关报告：</strong></p>
</div><p><strong>Patient Derived Xenografts/PDX Models Market</strong> <strong>- Global Forecast to 2030</strong></p>
<div class="lb-trans"><p><strong>患者来源异种移植/PDX 模型市场</strong> <strong>- 全球预测到 2030 年</strong></p>
</div><p><strong>Biomarkers Market</strong> <strong>- Global Forecast to 2030</strong></p>
<div class="lb-trans"><p><strong>生物标志物市场</strong> <strong>- 全球预测到 2030 年</strong></p>
</div><p><strong>Genomics Market</strong> <strong>- Global Forecast to 2030</strong></p>
<div class="lb-trans"><p><strong>基因组学市场</strong> <strong>- 全球预测到 2030 年</strong></p>
</div><p><strong>Precision Diagnostics &amp; Medicine Market</strong> <strong>- Global Forecast to 2029</strong></p>
<div class="lb-trans"><p><strong>精准诊断与医学市场</strong> <strong>- 全球预测到 2029 年</strong></p>
</div><p><strong>Proteomics Market</strong> <strong>- Global Forecast to 2031</strong></p>
<div class="lb-trans"><p><strong>蛋白质组学市场</strong> <strong>- 全球预测到 2031 年</strong></p>
</div><p><strong>About MarketsandMarkets™</strong></p>
<div class="lb-trans"><p><strong>关于 MarketsandMarkets™</strong></p>
</div><p>MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.</p>
<div class="lb-trans"><p>MarketsandMarkets™被《福布斯》评选为美国最佳管理咨询公司之一，依据其最新报告。</p>
</div><p>MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.</p>
<div class="lb-trans"><p>MarketsandMarkets™是增长咨询和项目管理领域的蓝海替代方案，利用人机结合的服务推动 B2B 领域进步组织的超常增长。我们对新兴技术的广泛视角使我们能够与全球客户共同创造超常增长。</p>
</div><p>Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.</p>
<div class="lb-trans"><p>如今，80% 的财富 2000 强公司依赖于 MarketsandMarkets，且每个行业前 100 家公司中有 90 家公司信任我们以加速其收入增长。我们拥有超过 13000 个全球客户，帮助企业在颠覆性生态系统中蓬勃发展。</p>
</div><p>The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.</p>
<div class="lb-trans"><p>B2B 经济正在见证 25000 亿美元新收入流的出现，这些收入流将在本十年内取代现有收入流。我们与客户合作开展增长项目，帮助他们通过我们的服务线——市场规模扩展、市场进入（GTM）战略到执行、市场份额增长、客户启用和思想领导力营销，来实现这一 25000 亿美元的机会。</p>
</div><p>Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.</p>
<div class="lb-trans"><p>基于 “给予增长” 的原则，我们与多家《福布斯》全球 2000 强 B2B 公司合作，以保持其未来准备状态。我们的洞察和战略由行业专家、尖端人工智能和我们的市场情报云平台 KnowledgeStore™提供支持，该平台整合研究并提供生态系统范围内的收入变化可见性。</p>
</div><p>MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.</p>
<div class="lb-trans"><p>MarketsandMarkets™ SalesPlay 是一款基于人工智能的收入智能助手，旨在帮助收入团队优先考虑合适的客户，及早识别关键变化，并在需求来临之前发现机会，从而自然地建立销售管道，并以更高的一致性完成交易。</p>
</div><p>To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.MarketsandMarkets™.com 或关注我们的 Twitter、LinkedIn 和 Facebook。</p>
</div><p>Contact:</p>
<div class="lb-trans"><p>联系方式：</p>
</div><p>Mr. Rohan Salgarkar</p>
<div class="lb-trans"><p>罗汉·萨尔加尔卡尔（Mr. Rohan Salgarkar）</p>
</div><p>MarketsandMarkets™ INC.</p>
<div class="lb-trans"><p>MarketsandMarkets™ INC.</p>
</div><p>1615 South Congress Ave.</p>
<div class="lb-trans"><p>南国会大道 1615 号</p>
</div><p>Suite 103, Delray Beach, FL 33445</p>
<div class="lb-trans"><p>103 套房，德尔雷海滩，佛罗里达州 33445</p>
</div><p>USA: +1-888-600-6441</p>
<div class="lb-trans"><p>美国：+1-888-600-6441</p>
</div><p>Email: [email protected]</p>
<div class="lb-trans"><p>电子邮件：[email protected]</p>
</div><p>Visit Our Website: https://www.marketsandmarkets.com/</p>
<div class="lb-trans"><p>访问我们的网站：https://www.marketsandmarkets.com/</p>
</div><p>Logo: https://mma.prnewswire.com/media/1868219/5909825/MarketsandMarkets_Logo.jpg</p>
<div class="lb-trans"><p>标志：https://mma.prnewswire.com/media/1868219/5909825/MarketsandMarkets_Logo.jpg</p>
</div><p>SOURCE MarketsandMarkets</p>
<div class="lb-trans"><p>来源：MarketsandMarkets</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9SU82MTYxMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxMDMwUFJfTkVXU19VU1BSX19fX19JTzYxNjEy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=IO61612&amp;Transmission_Id=202605181030PR_NEWS_USPR_____IO61612&amp;DateId=20260518"/></p>

10:30 ETCancer Biomarkers Market worth $54.48 billion by 2032 | MarketsandMarkets™

prnewswire

Illumina

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

标普健康医疗设备 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

美国制药 ETF - iShares

医疗业 ETF - Vanguard

标普全球医疗股指数 ETF - iShares

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

美国医药设备 ETF - iShares

奎斯特诊疗

安捷伦科技

ROCHE HOLDINGS AG

根据 MarketsandMarkets™的报告，到 2032 年，癌症生物标志物市场的价值预计将达到 544.8 亿美元